Understand the source comparison
Peptides Help with Immune Support: Comparison by Mechanism
The table below compares primary immune-modulating peptides by mechanism, targeted pathway, clinical evidence level, and practical application context. Thymosin Alpha-1 Thymic hormone restoration T-cell maturation (TLR2 → IL-2/IFN-gamma) Phase III trials in he
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares primary immune-modulating peptides by mechanism, targeted pathway, clinical evidence level, and practical application context.
- Thymosin Alpha-1
- Thymic hormone restoration
- T-cell maturation (TLR2 → IL-2/IFN-gamma)
- Phase III trials in hepatitis B, sepsis
- 1.6–3.2 mg SC 2x/week
- Strongest evidence for immunocompromised populations; effect measurable via CD4+/CD8+ counts
- Thymalin
- Polypeptide thymic extract
- Thymulin secretion, broad thymic support
- Russian clinical trials (n>1,200)
- 5–10 mg IM daily × 5–10 days
- Effective in elderly immune senescence; lacks Western Phase III validation
- LL-37 (Cathelicidin)
- Antimicrobial membrane disruption
- Direct bacterial lysis + neutrophil recruitment (FPR2)
- Preclinical + Phase II nasal formulation
- 10–20 µg/mL (topical/inhaled)
- Promising for mucosal infections; systemic delivery unresolved
- KPV Tripeptide
- NF-κB inhibition
- Pro-inflammatory cytokine suppression
- Phase II in IBD models
- 500 µg–2 mg oral/topical
- Selective anti-inflammatory without immune suppression; limited human data
- BPC-157
- Angiogenesis + tissue repair
- Indirect immune support via tissue healing
- Preclinical only
- 200–500 µg SC daily
- No direct immune pathway; supports recovery environment